Infants, children, and adolescents 6 months to <18 years with other conditions that may increase their risk of severe COVID-19 can consider a primary course of COVID-19 vaccine
Infants, children, and adolescents aged 6 months to <18 years with conditions other than severe immunocompromise that may increase the risk of severe COVID-19 and who have not previously received a dose of COVID-19 vaccine can consider a primary course based on a risk-benefit assessment.
Children and adolescents aged 5 to <18 years can receive a single primary dose.
Infants and children aged 6 months to <5 years can receive 2 primary doses and can consider a 3rd based on a risk benefit assessment. All primary doses should be given at least 8 weeks apart.
Further doses are not recommended.
Comirnaty JN.1 and Omicron XBB.1.5-based vaccines can be used in infants, children and adolescents.
Adolescents aged 12 to <18 years may receive Comirnaty JN.1 ≥12 years formulation (dark grey cap) and Comirnaty Omicron XBB.1.5 ≥12 years formulation (dark grey cap). Children aged 5 to <12 years can receive Comirnaty JN.1 5 to <12 years formulation (light blue cap) and Comirnaty Omicron XBB.1.5 5 to <12 years formulation (light blue cap).
Infants and children aged 6 months to <5 years can receive the Comirnaty JN.1 <5 years formulation (yellow cap) and Comirnaty Omicron XBB.1.5 6 months to <5 years formulation (maroon cap).
